Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
iTeos Belgium SA
With
The combinations evaluated will be: * EOS-448 combined with pembrolizumab, an anti-PD-1 antibody * EOS-448 combined with inupadenant an investigational adenosine A2A receptor antagonist * EOS-448 combined with dostarlimab an anti-PD-1 antibody * inupadenant combined with dostarlimab * EOS-448 combined with inupadenant and dostarlimab * EOS-448 combined with dostarlimab and standard of care chemotherapies in participants with NSCLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted